School of Medicine
Showing 781-790 of 1,185 Results
-
Karen Osilla
Associate Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)
Current Research and Scholarly InterestsDr. Osilla conducts health services research with a focus on delivering substance use services to underserved populations using innovative solutions that decrease health access disparities. Dr. Osilla has been conducting addictions research since 2006 and has been involved in clinical trials evaluating cognitive behavioral therapy, collaborative care, and motivational interviewing interventions (web and in-person) among youth, adult, military, family members, and other hard-to-reach populations.
-
Michael Ostacher
Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)
BioDr. Ostacher is Professor of Psychiatry and Behavioral Sciences. He is the Site Director for the Addiction Medicine Fellowship at the VA Palo Alto Health Care System, where he also serves as the Medical Director of the Pharmacology of Addiction Recovery Clinic, the Director of the Bipolar and Depression Research Program and the Co-Director of the VA/Stanford Exploratory Therapeutics Lab, the Director of Advanced Fellowship Training in Mental Illness Research and Treatment for MDs for the VISN 21 MIRECC, and the Site Director at the VA Palo Alto for Advanced Fellowship Training for Stanford. A graduate of Vanderbilt University School of Medicine, the Harvard School of Public Health, and Harvard Medical School, he completed his training at The Cambridge Health Alliance at Harvard Medical School in Adult Psychiatry, Public Psychiatry, and Geriatric Psychiatry, and is currently board certified in Psychiatry, Addiction Psychiatry, and Addiction Medicine. He is the Digital Content Editor for the journal Evidence-Based Mental Health and is on the editorial boards of Bipolar Disorders, the International Journal of Bipolar Disorders, the Journal of Clinical Psychiatry, Current Psychiatry, and Psychiatric Annals. His current research includes roles as Site Investigator for VA-BRAVE, multicenter, randomized trial comparing long-acting injectable buprenorphine to sublingual buprenorphine/naloxone, and trials of psychedelic drugs in psychiatric disorders in Veterans. With funding from NIDA, he studied, along with Jaimee Heffner, Ph.D. at the Fred Hutchinson Cancer Research Center in Seattle, smoking cessation in people with bipolar disorder using a novel online psychotherapy derived from Acceptance and Commitment Therapy. His primary research interest is in large clinical trials mental health and addiction, and the implementation of evidence-based mental health practices.
-
Heather Ryan Pankow
Life Science Rsch Prof 2, Psych/General Psychiatry and Psychology (Adult)
Current Role at StanfordLife Science Research Professional 2 in The Depression Research Clinic
-
Sara Pardej
Postdoctoral Scholar, Psychiatry
BioSara Pardej earned her BA in Psychology and BS in Cognitive Science at Marquette University. Afterwards, she attended the Clinical Psychology Doctoral Program at the University of Wisconsin-Milwaukee under the mentorship of Dr. Bonita P. Klein-Tasman, where she earned both her MS and PhD in Clinical Psychology. There, she worked on several studies focusing on youth with neurofibromatosis type 1 (NF1), including behavioral phenotyping work, psychometric studies, and a social skills intervention study. Her dissertation study, which was funded by a Young Investigator Award from the Children's Tumor Foundation, focused on examining event related potentials using EEG by comparing children with NF1 to children with idiopathic ADHD and unaffected children. She completed her Doctoral Internship in Clinical Psychology at Penn State Health in Hershey, Pennsylvania. While at Penn State, she also worked on research examining safety and psychopathology in youth with ADHD and/or autism. Her clinical interest is neuropsychology, and her research interests include issues of psychometrics, behavioral phenotyping, and the neuropsychological development (and subsequent areas of intervention) of individuals with NF1 across the lifespan.
